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Abstract
The immune system is able to act against cancer cells and consequently these cells have
developed a range of responses to evade or suppress the immune systems anticancer
responses. The concept of cancer immunotherapy is based on techniques developed to
restore or boost the ability of the immune system to recognize and target tumor cells. It
is known that colon cancer does initiate an immune response and that this type of cancer
initiates pathways and responses to evade or suppress the immune system. This chapter
will discuss some of the dominant therapies being developed to treat colon cancer based
on the concept of cancer immunotherapy. Cancer vaccines are based on the concept of
providing  the  immune  system  with  antigen  targets  derived  from  tumor-specific
molecules,  while  monoclonal  antibodies  involve  the  development  of  antibodies
specifically  targeting  proteins  expressed  on  the  surface  of  tumor  cells.  Antibody-
based  immunotherapy  has  further  applications  in  the  use  of  bispecific  antibodies
(BsAb), which are synthetic antibodies designed to be able to recognize two different
antigens  or  epitopes  and in  this  way can increase  the  immunoresponse and limit
immune evasion observed in mono-targeted therapy. Immune checkpoint inhibitors
target proteins that are responsible for keeping immune responses in check. Tumor cells
overexpress these proteins in order to evade the immune response. Blocking these
proteins  will  lead to  an increased immune response against  these  cells.  Cytokine-
based  immunotherapies  involve  the  use  of  the  immune  systems’  own  molecular
messengers that are responsible for a robust immune response, to boost the antitumor
response of the immune system. Oncolytic viral therapy is based on the use of viruses
that  selectively  infect  and replicate  in  cancer  and associated endothelial  cells  and
subsequently kills these cells. Adoptive immunotherapy involves the use of immune
cells from the patient to be cultured and altered in the laboratory and then reintro‐
duced  to  boost  the  immune  response.  This  is  normally  performed  with  T  cells.
Immunotherapy may be the next logical step in the development of an effective therapy
for colon cancer and other cancers. The combination of these therapies with tradition‐
al chemotherapy or radiotherapy has shown promise in cancer treatment.
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1. Introduction: immunotherapy
Tumor-associated antigens (TAAs) are antigens that can elicit a specific immune response.
Immune cells and immune-related components such as macrophages, neutrophils, comple‐
ment components,  γδ T cells,  natural  killer  (NK) cells,  NKT cells,  and certain cytokines
(interleukin (IL)-12, interferon gamma (IFN-γ)) and cells of the adaptive immune system,
including B lymphocytes, helper T cells (Th cells), and cytotoxic T lymphocytes (CTLs), are all
active against cancer cells [1]. TAAs are presented to the cells of the adaptive immune system
by cells such as dendritic cells (DCs) or other antigen-presenting cells (APCs). These antigens
are processed and presented by major histocompatibility complex (MHC) class I and class II
molecules leading to the activation of antigen-specific lymphocytes, resulting in antibody
production [1].
Colon cancer evades the immune system through the shift from Th1 to Th2 immune responses
[2] loss/downregulation of human leukocyte antigen (HLA) class I antigen processing and
presentation [3], defective DC function [4, 5], T-cell loss of signaling molecules [6, 7], escaping
death receptors, HLA G expression, alterations in transforming growth factor (TGF) beta
signaling [8], Increased vascular endothelial growth factor (VEGF) expression, impaired NK
activity, regulatory T-cell downregulation [9], and complement decay accelerating factor CD55
[2]. A shift is known to occur in the white blood cell composition with elevated numbers of
CD8 T cells in the initial stages, but an overall reduction in the numbers of circulating immune-
related cells. At the same time the levels of cytokines such as IFN-γ and tumor necrosis factor-
α (TNFα) are reduced during vascular invasion [10]. Antitumor T cells can be inhibited through
NO production by the enzyme arginase [11].
Immunotherapy can be divided into two main categories: passive and active immunotherapy.
Passive immunotherapy makes use of in vitro produced immunologic effectors that are capable
of influencing tumor cell growth. This includes monoclonal antibody (mAb) therapy and
adaptive transfer of antigen-specific effector cells. Active immunotherapy aims at inducing or
boosting immune effector cells [1].
2. Cancer vaccines
Cancer vaccines are active immunotherapeutic approaches that are intended to activate and
expand tumor-specific T cells to induce an antitumor response. Conventional vaccines are
preventative in nature, but current cancer vaccines activate the immune system to destroy
tumors once present. A range of tumor antigens have been identified. These include T-cell
Colorectal Cancer - From Pathogenesis to Treatment212
epitope peptides, defined carbohydrates of glycoproteins and glycolipids, antibody-based
anti-idiotype vaccines, plasmid DNA and recombinant viral vector vaccines, allogeneic or
autologous whole tumor cell vaccines, DC-based vaccines, oncolysates, or autologous heat-
shock protein (HSP)-peptide complex vaccines. An ideal prophylactic cancer vaccine would
be affordable, stable, and safe. It would induce effective immunity rapidly and require few
immunizations (ideally one) to induce protection [12]. This section aims to address advances
made in developing vaccines against colon cancer. This will include vaccines that are currently
in use and vaccines still undergoing clinical trials. It will report on the safety, side effects, and
efficacy of these vaccines.
Colon cancers express multiple immunogenic proteins, all of which may serve as targets for
the development of T-cell-mediated adaptive immune responses [10]. It is also known that
colorectal cancers do activate the immune system, leading to the attenuation of metastasis and
increasing the survival of patients [10]. In order to evade the immune response, colorectal
cancer suppresses the immune response or displays only weak immunogenicity. Additionally,
studies have shown that restoration or supplementation of the immune function toward these
tumors is possible [10, 13, 14]. Peptides used to inoculate a patient suffering from colon cancer
will be degraded and the resulting fragments will be endocytosed by APCs. These cells will
then present the antigen to the T cells. CTLs or CD8+ T cells induce apoptosis in tumor cells
through the release of granzymes and perforins and through the Fas death receptor pathway.
Type 1 CD4+ T cells and T-helper cells secrete cytokines leading to the recruitment of CTLs,
macrophages, and NK cells. These secrete cytokines that activate cytotoxic pathways [11]
(Figure 1). It is also known that colorectal cancers do activate the immune system, leading to
the attenuation of metastasis and an increase in the survival rate and time of patients [10]. The
effectiveness of peptide vaccines can be enhanced by altering the amino acid sequence of the
peptide to enhance the interaction with the T-cell receptor (TCR), to improve binding to MHC,
and finally to improve biostability and reduce degradation by proteases [11].
2.1. Evasion of the immune system by altered ligand expression
One mechanism utilized by cancer cells to evade the immune system involves the expression
of FasL. This ligand binds to the Fas receptor present on CTL, leading to the CTL to undergo
apoptosis. The expression of FasL leads to the increased resistance to Fas-induced apoptosis.
Altered peptide ligands (APLs) are analogs of immunogenic peptides which are ligands for
TCRs. These altered ligands bind the TCR, but does not lead to lysis of the tumor cell [11].
Regulatory T cells can inhibit antitumor immunity by upregulating cell membrane molecules
that lead to the inhibition of effector T-cell activation and function. Cancer cells have defective
antigen presentation allowing them to avoid recognition by the immune system. This is
accomplished by reduced expression of MHC I, antigen-processing machinery, or Tumor-
associated antigens themselves [11].
2.2. Tumor-associated antigens (TAAs)
Defined TAA epitopes can be used to vaccinate cancer patients. The peptide fragments are
presented by the two MHC proteins, MHC classes I and II (HLA I and II) to the TCRs. MHC
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class I presents the vaccine-derived peptide to naive CTLs. Primed CTLs recognize the tumor
antigen on the surface of the tumor and send out a death signal to the tumor. Helper T cells
are generated by MHC class II proteins [11] (Figure 1). However, there are not many specific
peptides that can be targeted as cancer specific. In order to increase uptake and presentation
of the antigens by APCs, an adjuvant is added [1]. Another strategy is to inject the DNA
sequences coding for specific TAAs to be taken up. The target ill be transcribed into mRNA,
translated into a protein, and processed into peptides by APCs. This can be done by using
viruses engineered to express TAAs. However, the immune system may preferentially react
to the viral antigens rather than the TAAs, leading to the attenuation of the antitumor immune
response [1]. The earliest example of the therapeutic use of tumor antigens was in the form of
crude tumor lysates being administered to patients. These lysates are still used as a means to
prime DCs, facilitating peptide presentation [11]. This is because the ideal source of TAAs is
all the TAAs the tumor itself expresses. By incubating DCs with dead tumor cell lysate, these
antigens will all be presented by MHC class I (cross-presentation) and MHC class II pathways.
This will result in a diversified immune response involving CTLs as well as CD4+ T-helper
cells [1].
The use of tumor lysates has largely been superseded by the use of synthetic peptides. These
have certain advantages over tumor lysates. They provide a higher amount of specific antigen
and allow for modification of the target peptide. It is also easy to monitor the immune response
to vaccination with a single peptide as only one CTL type requires evaluation [11]. Tumor-
specific antigens (TSAs) are mutated or virus-derived epitopes and contain unique immuno‐
genic neo-antigens that can be recognized by the immune system. These include N-RAS and
p53 [1].
Figure 1. Antitumor effect of peptide vaccine therapy: following introduction of peptide vaccine to the bloodstream, it
is processed and presented by the APC leading to the activation of CD4+ helper T cells and CD8+ cytotoxic T cells.
Interaction between MHC I molecules on APC and TCR during antigen presentation facilitated by CD8 molecule leads
to the generation of tumor-specific CTLs capable of lysing tumor cells.
Colorectal Cancer - From Pathogenesis to Treatment214
Peptides Mechanism Study details References
Tyrosine kinase receptor
ephrin type-A receptor 2
(EphA2-derived peptide)
EphaA2 EphA2-specific CTL High level of immunity against colorectal
cancer in murine model
[15]
RNF43-721 Phase 1 clinical trial [16]
ABT-737 Inhibition of antiapoptotic Bcl-2
family
Sensitized cancer cells in mouse colon cancer
model
[17]
Epitopes of HER2, MVF,
GMP, and n-MDP
Multiple targets Phase 1 clinical trial [18]
Endoglin Inhibition of angiogenesis Inhibition of tumor growth in mouse model [19]
CEA CEA691 Induction of tumor-specific
CTLs
Increase in survival rate in colon carcinoma
mouse model
[20]
OX40L – TNF family
protein
Inhibition of tumor growth in mouse model [21]
Mucin 1: MUC1 a cell
surface-associated protein
Stimulation of antigen-specific CTL,
abundant secretion of IFN-γ.
Tumor burden was significantly reduced in
colon
cancer mouse model
[22]
Heat-shock protein Gp96 Induction of tumor-specific
CTLs
Two-year overall survival and disease-free
survival were significantly improved
SART3-tumor-rejection
antigen
Induction of tumor-specific
CTLs
Increased cellular immune responses to the
tumor. No improved clinical outcome 
[23, 24]
Lck-derived peptides Induction of tumor-specific
CTLs
[24]
Survivin-2B Induction of
HLA-A24-restricted cytotoxic T
cells resulting in
high toxicity against HLA-A24-
positive survivin-2B-positive
cancer in vitro 
Increased proportion of peptide-specific
CTL. No significantly improved clinical
outcome
[25]
βHCG CTP37-DT
(Avicine)
Phase II trials showed improved patient
survival
[26]
CDX 1307 Fusion between βHCG and an
antibody against the mannose
receptor
Phase I trial. Inoculation leads to DC
activation as well as cytotoxic T-cell activity
against tumor cells
[27]
p53 (SLP) p53-specific CD4+ Th cell SLP is
a p53 synthetic long peptide
Antitumor response against p53-
overexpressing tumors. The p53-SLP vaccine
induces p53-specific T-cell responses
[10]
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Peptides Mechanism Study details References
EGFR2 gefitinib or
erlotinib 
EGFR mutations enhance
tyrosine kinase activity in
response to EGF, increasing the
efficacy of anti-EGFR
In a phase I trial, the vaccine elicited
antibody response
phase II cancer
[28]
Gastrin: G17DT
(gastroimmune)
Antigastrin-17 immunogen,
raising antibodies that blockade
gastrin-stimulated tumor
growth 
Phase II trials showed gastroimmune
combined with irinotecan chemotherapy
increased patient survival
[29]
Examples of peptide-based vaccine targets, their mechanism, as well as the current results of any trials performed
using the vaccines to treat colon cancer.
Table 1. Peptide targets and mechanism of action.
Discussed below are examples of peptide-based vaccines and their targets that have been used
to treat colon cancer. More examples are listed in Table 1. Beta human chorionic gonadotropin
(βHCG) is not produced by normal colorectal cells. The increase in the expression of this
antigen in colon cancer cells leads to an increase in tumor invasiveness, higher metastatic
incidence and promotion of tumor growth, neovascularization, and immune system suppres‐
sion. This makes it an attractive target for the development of an antibody-based vaccine [10].
Carcinoembryonic antigen (CEA) is an oncofetal antigen that can serve as a target for vaccine
development. It is found overexpressed on the surface of colon cancer cells, with very low
levels of expression on normal cells. Unfortunately this protein is normally expressed during
fetal development and is therefore tolerated by the immune system. This led to the creation of
an artificial CEA. CeaVac is based on anti-idiotypic antibodies and mimics CEA [10]. Another
oncofetal protein 5T4 is a leucine-rich membrane glycoprotein. Once again it is nearly absent
in normal tissues but is overexpressed in colon cancer cells and developing cells. Its presence
is associated with poor survival. The drug TroVax uses 5T4 with a pox virus vector and a
modified vaccinia virus. Preclinical trials in mouse models resulted in a 90% reduction of tumor
burden [10].
Onyvax-105 is another anti-idiotype antibody mimicking the glycosylphosphatidylinositol-
anchored protein CD55. CD55 regulates complement activation protecting cells against
complement attack thereby enhancing tumor cell survival. The gastric acid–stimulating
hormone gastrin is a hormone the precursors of which are overexpressed in colon cancer,
where they act as growth factors. This leads to increases in angiogenesis and cell proliferation.
Vaccines raised against this protein would therefore result in inhibition of cell growth,
proliferation, and metastasis [10]. Onartuzumab is a mAb that targets human growth factor
receptor (HGFR). It is a monovalent HGF antagonist antibody against MET Proto-Oncogene,
Receptor Tyrosine Kinase that benefits patients who overexpress HGFR [30].
The FANG TM vaccine consists of tumor cells from the patient and a plasmid expressing
granulocyte-macrophage colony-stimulating factor (GM-CSF) and bifunctional short hairpin
RNAfurin (bi-shRNAfurin). The growth and production of DCs are induced by GM-CSF. The
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enzyme furin transforms precursor proteins into active proteins and the presence of bi-shRNAi
furin inhibits the production of active proteins. This particularly inhibits the production of
TGF β1 and 2 (TGFβ). Overexpression of TGFβ is associated with cancer progression and
immune suppression by inhibiting GM-CSF and the consequent production of dendritic and
other APCs. The vaccine therefore prevents the overexpression of TGFβ and leads to immune
cell activation and the inhibition of cancer cell proliferation [30]. The vaccine was manufac‐
tured using GM-CSF and IL-13 to generate DCs from monocytes. The DCs were loaded with
6HLA-A*0201-binding peptides derived, among others, from CEA, MAGE-2 (melanoma
antigen overexpressed in gastrointestinal cancer), and HER2/neu [10, 30].
TroVax is an attenuated strain of vaccinia virus that encodes the 5T4 protein. This protein is
an oncofetal antigen and is a transmembrane glycoprotein. It is highly expressed in colon
cancers and is virtually absent in normal tissue. The receptor is thought to play a role in
metastasis and the expression level increases with the advancement of the stage of the cancer.
This vaccine is able to induce an effective immune response, as it results in the formation of
antibodies for both the 5T4 antigen and the viral particle [31].
2.3. Heat-shock proteins (HSPs)
HSPs are widely expressed in tumors, where they promote cancer progression. HSP 72 and
glucose-regulated protein 96 (gp96) are two of these proteins that are highly expressed in colon
cancer [32]. These proteins are thought to play a role in cell growth and signal transduction
and expression of these proteins is higher in tumors undergoing metastasis. This makes them
useful as diagnostic and prognostic markers. However, this expression is not related to patient
survival [32].
HSPs enhance antigen-specific tumor immunity as they play an important role in the presen‐
tation of antigens to CD8+ T cells through the MHC I pathway. This is because of the roles HSP
70s play as chaperones and in the transport of peptides to the heterodimeric transporters
associated with antigen processing [33]. Similarly gp96 is a major chaperone involved in the
lumen of the endoplasmic reticulum (ER), where it facilitates the folding of the MHC Iβ-2
microglobulin-peptide complexes in the ER [34].
Vaccines based on HSPs have been tested in animal trials and been found to be highly effective
in the treatment of cancers [32, 35]. The function of the HSP in transporting and presenting
other peptides as surface antigens has led many researchers to propose that HSPs can be used
to create a HSP target protein fusion. This booster strategy would therefore enhance the ability
of the target protein to be used as an antigen by T cells [36]. Two of these proteins that can be
coupled to HSPs to improve their immunogenicity and usefulness as a cancer vaccine are
alpha-fetoprotein (AFP) in hepatocellular carcinoma and CD44 in colonic carcinomas [32].
3. Targeted therapy: monoclonal antibodies
Recently, a new class of targeted agents have been identified, which bind to the ligand or the
extracellular domain of a receptor. This results in alteration of intracellular signal transduction
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pathways which will affect cell proliferation, dedifferentiation, inhibition of apoptosis, and
stimulation of neoangiogenesis [37]. This section will look into VEGF-targeted drugs (e.g.,
ramucirumab (Cyramza®) and bevacizumab (Avastin®)), EGFR-targeted drugs (e.g., cetuxi‐
mab (Erbitux®) and panitumumab (Vectibix®)), and others such as those that target kinases
[37].
3.1. Bevacizumab and ramucirumab
VEGF is a potent angiogenic factor and functions by binding to one of three VEGF receptors
located on endothelial cells and angioblasts. The VEGF receptor-2 is overexpressed on up to
50% of colorectal cancer cell surfaces. VEGF-A and other proangiogenic factors promote the
degradation of the extracellular matrix. This enables proliferation and migration of endothelial
cells [37]. The ligands of the VEGF family include VEGF-A, VEGF-B, VEGF-C, VEGF-D, and
VEGF-E; and the receptors are VEGFR-1, R-2, and R-3. In colon cancer the ligand that is most
abundant is VEGF-A [38]. Sustained angiogenesis is a hallmark of cancer; and targeted
inhibition of blood vessel development is an established strategy for antitumor therapy [38].
Anti-VEGF therapies have been associated with a survival benefit across multiple malignan‐
cies including colon cancer [38].
Bevacizumab is a humanized mAb against VEGF and it acts by preventing ligand binding by
binding to VEGF. This prevents downstream intracellular signal transduction; however, the
response to bevacizumab appears to be independent of VEGF expression or high microvessel
density (MVD) [37]. MVD assessment is a good predictor of metastasis, with selective anti‐
bodies, such as endoglin, distinguishing between tumor neovascularization and preexisting
vessels. VEGF expression is highest in patients with metastatic tumors and the level is
associated with cancer stage [38]. Bevacizumab is typically used in combination with other
chemotherapeutic agents, and it is also indicated in improving the delivery of chemotherapy
by changing tumor vasculature and decreasing the elevated interstitial pressure in tumors.
The combination of therapies results in improved survival [38].
Ramucirumab is a fully humanized IgG1 mAb targeting the extracellular domain of VEGF
receptor 2 (VEGFR2). Large-scale trials have indicated that ramucirumab shows promising
antitumor effects and is well tolerated. The origin of this antibody was through the use of a
large phage display library with tailored in vitro selection methods to identify a high-affinity
antibody [39]. Measurement of VEGFA and soluble VEGFR1/2 during phase I trials of the
antibody indicated that there is an increase in the expression of VEGF as well as a decrease in
VEGFR1/2 levels. These changes were not dose related, which suggests that the receptor was
saturated [39]. Phase I trial results were promising and phase II trials resulted in a high
percentage of patients presenting with progression free survival at 6 months. Phase III trials
showed an increase in overall patient survival [39]. Adverse reactions to ramucirumab
included hypertension, vascular thrombotic events, and proteinuria [40].
Aflibercept is a recombinant fusion protein consisting of the second immunoglobulin (Ig)
domain of VEGFR-1 and the third Ig domain of VEGFR-2, fused to human IgG1. It exhibits
affinity for VEGF-A, VEGF-B, and PlGF. The antibody displayed effective activity against colon
cancers with improvements in the primary endpoint of overall survival and overall response
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rate, as well as displaying a high degree of tolerability in patients [40]. VEGFR-1 also plays a
role in colon cancer and inhibiting its signaling could also play a role in cancer treatment. An
antibody developed to target this receptor named IMC-18F1 has been developed. This is a
high-affinity human VEGFR-1-neutralizing antibody that specifically binds the extracellular
domain of VEGFR-1. It exhibits antiangiogenic and antiproliferative activity [40].
3.2. Panitumumab and cetuximab
The epidermal growth factor receptor (EGFR) is a target for the therapeutic monoclonal
antibodies panitumumab and cetuximab the treatment of metastatic colorectal cancer.
Panitumumab is a fully human Ig G2 mAb that binds the EGFR extracellular domain with high
affinity and inhibits ligand-induced EGFR tyrosine phosphorylation, tumor cell activation,
and tumor cell proliferation (Figure 2). Cetuximab is a chimeric human-mouse IgG1 mAb [41].
Cetuximab and panitumumab are both Food and Drug Administration (FDA) approved for
advanced colorectal cancer therapy, and both have clear benefits for colon cancer treatment of
most patients. The exception is those patients that carry KRAS mutations at codons 12 and 13
[42]. KRAS mutations occur in approximately 35–40% of colorectal tumors, and KRAS is a
member of the rat sarcoma virus (Ras) gene family of oncogenes and is involved in integrating
the signaling cascades controlling gene transcription, including many EGFR-mediated
pathways [41]. The ligands of the EGFR transmembrane tyrosine kinase receptor include EGF,
TGFα, epiregulin, amphiregulin, β-cellulin, and heparin. EGFR activates downstream signal‐
ing pathways such as the Ras/Raf/mitogen-activated protein kinase (MAPK) pathway, the
phosphatidylinositol 3-kinase (PI3K)/AKT pathway, and the signal transducer and activator
of transcription (STAT) pathway. These downstream pathways activate cellular survival,
proliferation, invasion, metastasis, and angiogenesis. Abnormal activation of the EGFR
signaling network due to excessive overexpression is common in colon cancer (Figure 2). EGFR
is composed of an extracellular ligand-binding domain, a hydrophobic transmembrane region,
and an intracellular domain with tyrosine kinase activity [41, 43].
Cetuximab competes with EGFR ligands, such as EGF or TGFα, with a high affinity
(Kd = 1 × 10−10 M). This results in the inhibition of cell cycle progression and arrest of cell cycle
in G1 phase, inhibition of angiogenesis, inhibition of metastasis by reduction of production of
matrix metalloproteinase, inhibition of apoptosis, and potentiation of antitumor activities of
chemotherapy and radiotherapy [43]. Panitumumab treatment results in improved clinical
outcomes in patients with chemotherapy-refractory colon cancer [41]. Panitumumab also has
a high affinity for EGFR (Kd = 5 × 10−11 M) and acts to arrest cell cycle progression and block
cancer growth; however, it is an IgG2 and does not act through antibody-dependent cell
cytotoxicity [43].
Using a single type of mAb to block a single transduction pathway may only have a limited
effect, as tumors can shift to other alternate pathways. One solution is to combine monoclonal
antibodies to block two signaling transduction pathways [44]. Use of multiple monoclonal
antibodies has other advantages including limited overlapping toxicity and few to no phar‐
macokinetic interactions between antibodies. However, some studies indicate that certain
combinations such as bevacizumab with cetuximab or panitumumab lead to shorter survival
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and increased toxicity in advanced colorectal cancer compared to therapy with a single
antibody [44]. The addition of panitumumab to chemotherapy improves clinical outcomes
among patients with wild-type KRAS [41]. Other biomarkers that affect the efficacy of
panitumumab include mutations in the BRAF and PIK3CA genes [41]. An important side effect
of panitumumab treatment is the occurrence of skin toxicity; however, occurrences of skin
toxicity correlate with favorable outcomes for patients [41, 43].
Figure 2. Mechanism of action of anti-EGFR mAbs. The binding of these mAbs on EGFR prevents the dimerization and
the activation of EGFR.
4. Immune checkpoint inhibitors
During the progression of tumor development, the cancer cells undergo changes to escape
immune surveillance. In order to accomplish this, a large enough number of the tumor cells
must escape in order for there to be an equilibrium between tumor growth and tumor killing
[1]. Normally, tumor-infiltrating lymphocytes (TIL) would control the progression of cancers;
however, cancer cells can evade this response using a process known as T-cell exhaustion. This
occurs due to the expression of inhibitory receptors. Blocking these receptors through the use
of inhibitory molecules or monoclonal antibodies is known as immune checkpoint inhibition
[45]. The immune system depends on multiple checkpoints to avoid overactivation in healthy
cells. These inhibitory molecules expressed by the cancer cells take advantage of these
checkpoints to escape detection by the immune system. They will often express molecules that
serve as “immune checkpoints,” by so doing; a message is sent to the immune system that an
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immune response is not necessary. Drugs are being developed to block immune checkpoint
molecules from binding to their molecular partners, thus allowing the body to elicit an immune
response and therefore attack cancer cells. An analysis of the expression patterns in colon
cancers revealed a large overexpression of immune checkpoint-related proteins [46].
The programmed death-1 (PD-1) checkpoint is blocked in most cancers and blocking the
pathway with antibodies to reactivate this checkpoint is a viable cancer therapy [47]. Recent
insights indicate that blockade of the PD-1 checkpoint exists in many cancer patients and a
repertoire of tumor-specific or tumor-selective T cells can be reactivated to achieve tumor
therapy [48, 49]. Blocking the PD-1 pathway with antibodies results in durable tumor regres‐
sion. Programmed death-ligand 1 (PD-L1) is a transmembrane receptor that plays a role in
suppressing the immune system by suppressing the proliferation of CD8+ T cells and to lower
the level of antigen particles by regulating apoptosis. PD-1, expressed on T cells, B cells, and
other immune effector cells, interacts with this receptor, resulting in a negative signal to the T
cell. Expression of PD-L1 in tumor biopsies shows that this pathway acts to block antitumor
immune responses [46]. PD-1 has two ligands, PD-L1 and PD-L2. Tumor cells expressing PD-
L1 are associated with poor outcomes for patients. Targeting these ligands prevent T-cell
exhaustion and promotes T-cell recognition of tumors [45]. PD-L1 also binds to the co-
stimulatory molecule CD80, implying that CD80 has the potential to facilitate antitumor
immunity by inhibiting the PD-1 suppressive pathway [47].
Figure 3. Immune checkpoint interactions and antibody-based inhibition on T cells. CTLA-4 inhibition can be per‐
formed by inhibiting CD28 co-stimulation (through binding with its ligands CD80 or CD86) that is required to com‐
plete T-cell activation. The PD-1/PD-L1 pathway can be inhibited by targeting its inhibitory role. Here it interacts with
PD-L1 on the tumor cell. Inhibiting this interaction results in a more robust targeted antitumor immune response.
Ipilimumab is a mAb that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4),
which normally negatively regulates the activity of T cells. This antibody was the first
checkpoint-blocking antibody to be approved by the US FDA for cancer treatment; CTLA-4 is
a member of the Ig superfamily of receptors, which also includes PD-1, TIM-3 (T-cell Ig and
mucin domain-containing protein 3), BTLA (B and T-lymphocyte attenuator), and VISTA (V
domain Ig suppressor of T-cell activation). Use of this drug enhances the antitumor activity of
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CD8 T cells and inhibits the suppressive function of Tregs [45]. This was followed by a second
antibody, pembrolizumab, which targets the programmed death 1 (PD-1; CD279) molecule
[50] (Figure 3). Trials of these antibody therapies have only shown modest clinical benefits,
and this may indicate that tumors use multiple and nonoverlapping immunosuppressive
mechanisms to evade the immune response [45]. Multiple studies indicate that effective
therapy involves the targeting of multiple immunosuppressive pathways [51].
Tumor cells can also evade the immune system through the production of extracellular
adenosine by CD73 which is expressed on lymphocytes and endothelial and epithelial cells.
CD73 performs an endothelial cell barrier function, protecting cells from ischemia and
regulating immune responses. This receptor is overexpressed in many types of cancer, with
high CD73 expression being associated with poor outcomes for patients due to increases in
tumor immune escape and metastasis [45]. Blocking CD73 can induce potent antitumor
immune responses. Additionally the inhibition of molecular pathway components upstream
of CD73 such as CD39 also has similar therapeutic effects. This treatment can also be used to
supplement immune checkpoint therapies that make use of anti-CTLA-4 and anti-PD-1 mAbs,
to increase the effectiveness of such therapies [45].
Another strategy to target immune checkpoints is the use of small molecule drugs that target
critical survival pathways. These include Gleevec and ibrutinib, both of which are tyrosine
kinase inhibitors. Ibrutinib is a covalent inhibitor of BTK (Bruton’s tyrosine kinase), a key
enzyme in B-cell receptor signaling [49].
Controlling the immune response to cancer cells through the use of anti-inflammatory drugs
to control the inflammatory components reduces the risk of developing certain types of cancer.
Aspirin is able to reduce the incidence of colon cancer and slow down tumor progression.
Cyclooxygenase (Cox) enzymes 1 and 2 are the targets of aspirin. These enzymes are overex‐
pressed in tumor cells. Immunosuppressive drugs such as cyclosporine A (CsA) and tacroli‐
mus (FK506) inhibit the calcium/calmodulin-dependent phosphatase calcineurin, which acts
upon members of the nuclear factor of activated T cells (NFAT) [52]. These transcription factors
are important for cytokine production by T cells and are required for the normal function of
B cells, DCs, and mast cells. Expression of NFAT family members leads to tumor suppression
[53]. Treatment of tumor cells with CsA is capable of inducing necroptosis and a mild G0/G1
cell cycle arrest [52].
5. Cytokines
Cytokines are signaling proteins produced by white blood cells that help control the growth
and activity of immune system cells. The two types of cytokines that are used in the treatment
of cancer are IFNs and ILs. Cytokines stimulate a broad-based immune response as opposed
to generating a targeted response to a specific antigen [54]. Tumors secrete factors to recruit
inflammatory cells and/or activate stromal cells. Inflammation plays a major role in tumor
promotion and progression. The soluble factors that drive inflammation are cytokines and
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chemokines produced by tumor cells themselves and by the cells recruited to the tumor
microenvironment [55].
Several cytokines are capable of activating and recruiting specific immune cells that can
enhance antitumor immunity; these include IL-2, IL-12, IL-15, TNFα, and GM-CSF. These
cytokines can be used as single-agent therapies or in combination with other immunothera‐
peutic strategies. GM-CSF immunization leads to APC recruitment. Tumors activate Stat3 and
Braf, which leads to the release of IL-10, inhibiting the tumoricidal activity of NK cells. Stat3
activation in DCs leads to these cells becoming tolerogenic DC [11].
Additionally, TNFα, hepatocyte growth factor, PDGF, and FGF19 activate Wnt/β-catenin
signaling in tumor cells. This is the oncogenic pathway activated in the majority of colon
cancers. This pathway results in β-catenin accumulation in the cytoplasm, which activates cell
growth and differentiation pathways. IL-1β is a potent activator of Wnt signaling in colon
cancer cells leading to increased survival of colon cancer cells [55].
Oncogenic signaling through the Wnt and NF-kB pathways is activated through TNFα.
Pharmacological inhibition of TNFα by neutralizing TNFα antibodies has been used to treat
both irritable bowel disorders and colon cancer. Results from trials using enbrel or remicade
suggest that these neutralizing antibodies have activity against colon cancer cells. TNFα
signaling initiates NF-kB signaling. NF-kB is continuously expressed in certain tumors, leading
to enhanced survival by protecting the tumor cells from apoptosis. Treatment with the
TNFα antagonist, etanercept led to inhibition of Wnt/β-catenin6 signaling as seen by the ,
reduced expression of active β-catenin [55].
5.1. Interleukins 1β, IL-6, and IL-1
The proinflammatory cytokine IL-1β is produced by activated macrophages. In turn, IL-1β
induces the expression of TNFα, IL-6, IL-8, IL-17, Cox-2, and PGE2, promoters of tumor cell
growth. Inducing the expression of IL-1β leads to increased incidence of cancer in wild-type
mice. The IL-1β signaling pathway functions through the receptors IL-1RI and IL-1RII to
induce NF-kB activity. The pathway involves the two adaptor proteins, MyD88 and IRAK.
Macrophages are stimulated to release IL-1β and activate NF-kB and Wnt pathways, but
IL-1β signaling requires STAT1. The silencing of STAT1 expression leads to decreased IL-1β
release and prevented cancer cell growth [55].
IL-6 is secreted by stimulated monocytes, fibroblasts, and endothelial cells, macrophages, T
cells, and B lymphocytes. Macrophages are stimulated by colon cancer cells to produce IL-6
and activate STAT3 in tumor cells. Inhibition of IL-6 signaling interferes with the growth of
tumor cells and protects them from apoptosis. Research indicates that decreasing the expres‐
sion or inhibiting the activity of STAT3 may have adverse effects on tumor promotion.
Targeting STAT3 will affect the expression of β-catenin and the co-expression of STAT3 and
β-catenin is associated with poor survival of colon cancer patients [55].
A subset of T-helper cells produces the cytokines IL-17, IL-22, and TNFα (Th17 cells). Paneth
cells also produce IL-17. Th17 cells require IL-6, TGFβ, IL-1β, and IL-23, while IFN-γ and IL-4
negatively regulate differentiation of Th17 cells. IL-17 induces IL-6 and STAT3, promoting the
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survival of cancer cells. This cytokine may also have an anticancer function by enhancing
antitumor immunity [55].
5.2. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
TRAIL (also known as Apo2L) activates the apoptotic cascade. Tumor cells can evade this
apoptosis signal through the action of β-catenin. TRAIL’s role in tumor surveillance has been
confirmed in knockdown experiments and is a promising candidate to be used in cancer
therapy, because it selectively kills cancer cells while leaving normal cells unharmed [55].
Sorafenib a Raf kinase inhibitor sensitized A TRAIL –resistant colon cancer line to TRAIL-
induced apoptosis by preventing NF-kB-dependent expression of the antiapoptotic genes,
IAP2 and MCl-1.
6. Oncolytic virus (OV) therapy
Over a century ago, researchers observed that viral infection both in human and animal models
results in the expression of targets that can be recognized by T cells and/or antibodies.
Subsequently, vaccination has been used to treat an array of diseases such as hepatitis B virus
and human papillomavirus 15 which can cause liver and cervical cancer respectively. Vacci‐
nation against infections is used to induce neutralizing antibodies that act prophylactically.
However, with regard to cancer vaccination, cancer vaccine candidates should induce and
expand immune responses that can cause disruption of biological pathways that support
cancer growth.
The concept of cancer immunotherapy is based on the ability of the immune system to
recognize cancer cells and affect their growth and replication. Researchers have observed that
cancer regression would occur spontaneously in patients after viral infection [56, 57]. For
example, studies conducted by Lindeman and Klein 1967 showed that oncolysis of tumor cells
by influenza virus increased immunogenicity of tumor cell antigens. The recent advances in
successful sequencing of the cancer genome together with insights into how tumors evade the
immune system have led cancer research to evolve from searching for a gene that causes
individual cancer to one that blocks or disrupts biological pathways that support cancer
growth [58, 59]. As a result, cancer vaccines are now being designed with the aim to boost the
immune system to protect itself from carcinogenesis and progression of cancer. In 2010, the
FDA approved Provenge which is a therapeutic vaccine for cancer [60]. It is designed to treat
advances in prostate cancer and has shown to increase the survival rate. The success of
Provenge resulted in stimulating the interest in the development of other therapeutic cancer
vaccines.
In recent years, OV has been shown to be effective in treating cancer in both preclinical models
and clinical trials. Toda and coworkers showed that genetically modified oncolytic HSV G207
is a potential cancer vaccine for induction of specific antitumor immunity in CT26 colon cancer
cells [64, 61, 62]. This type of immunotherapy is largely dependent on the network of the host
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immune system to fight cancer by (i) boosting the patient’s immune system, (ii) decreasing
cancer-induced immunosuppression, and (iii) increasing the immunogenicity of the tumor
itself [63, 64]; OVs can be RNA- or DNA-based virus derived from human or animals.
Figure 4. Immunogenic cell death of cancer cells induced by oncolytic viruses. An oncolytic virus selectively replicates
in tumor cells, leading to induction of the death of these cells, presenting destruction signals on the cell surface and
consequent release of danger signals from necrotic cells. Apoptotic bodies are engulfed by APC, and TAAs are proc‐
essed and presented along with MHC complex and co-stimulatory molecules. The released DAMPs (and PAMPs) acti‐
vate and mature DCs, and TAAs are cross-presented to naive T cells. This process can be further enhanced at different
steps by other immunomodulatory agents (in a combination strategy). The resulting cytotoxic immune response
against tumor and associated stromal cells, involving CD4+ and CD8+ T cells, may help in complete eradication of tu‐
mor mass. Additional immunotherapies targeting DCs, T cells, and the immunosuppressive TME can further enhance
this antitumor immune response.
OV selectively infects and replicates in cancer and associated endothelial cells and subse‐
quently kills these abnormal cells without harming the normal cells. The selectivity of OV can
be an inherited feature of the virus or due to genetic engineering [56, 65]. OV therapy has
multiple antitumoral activities including direct effect by cytotoxic cytokines released upon
infection by tumor residents or infiltrating immune cells [66, 67]. The lysis-dependent cytore‐
ductive activity activates innate immune receptors when immunogenic cell debris is taken up
and cross presented by APCs (Figure 4).
OVs also directly affect various signaling pathways which are implicated in cancer such as
Ras, Wnt, anti-apoptosis, and EGFR [66, 68, 69]. The altered signaling pathway creates a
favorable environment for OV replication resulting in Cells infected with these viruses
Current Immunotherapeutic Treatments in Colon Cancer
http://dx.doi.org/10.5772/63212
225
showing sustained proliferation, resisting cell death, evading growth suppressors and
escaping immune surveillance. Cancer cells also show increased genomic instability and DNA
damage stress, which is favorable to OV replication [70–72]. Genetic manipulation of OV
enables these viruses to be (i) safe for use as a vaccine, (ii) highly selective for specific cancer
type, and (iii) altering virus tropism. In comparison with current regimes for cancer treatment,
OVs are advantageous because (i) they have a low chance for generation of resistance because
they use multiple ways to exert cytotoxicity and (ii) virus dose in a tumor increases with time
due to in situ virus replication whereas in the classical drug Pharmacokinetics, dose decreases
with time [71, 73].
The major drawbacks in the use of OV include nonimmune human serum, development of
anti-OV antibodies resulting from the use of human virus, and appropriate delivery into the
tumor. Various delivery mechanisms have been explored to enable delivery of OV to tumor
cells. For an example, cell carriers such as neural stem cells and myeloid-derived suppressor
cells have been used to deliver OV to specific tumor cells. The cells protect the virus from anti-
OV antibody neutralization, thereby facilitating virus deliver [71, 73]. In using OV to treat
colon cancer, ONYX-015 has advanced to phase II clinical trials and is used in combination
with chemotherapy [74, 75]. Recently, adenovirus 5 (PSE-EA1 and E deleted) has been
approved to treat prostate cancer in China giving hope to development of OV as an alternative
cancer treatment.
7. Bispecific antibody
Antibody-based therapy has been explored in treating a range of diseases and is promising to
be a success with the FDA having approved more than 13 monoclonal antibodies for treatment
of cancer (see Section 2). Furthermore, over 100 antibodies are at different stages of clinical
trials. Medical researchers have explored the properties of antibodies which are (i) highly
specific in binding their targets and (ii) are nontoxic for medical application using technologies
such as hybridoma and phage display for antigen targeting [76–79]. Also, new technologies
have been employed to manipulate antibodies for wide application. For example, the conven‐
tional antibody which is made up of two identical pairs of heavy and light chain linked together
by disulfide bonds is monospecific and bivalent. Using a hybridoma technology, a fusion can
be created between two hybridoma resulting in quadromas with two different heavy and light
chains as a result of random pairing, thus forming molecules that do not occur in nature (Figure
5A). Antibodies produced by these methods have an ability to bind different species but could
also be nonfunctional [77, 79, 80].
Conventional antibodies posed various challenges to therapeutic application due to inade‐
quate exposure to the tumor as a result of their size (150 kDa) and impaired interactions with
the immune system. Using enzyme-based antibody digestion, full antibodies may be truncated
into Fc and Fab regions (Figure 5A). The Fab region which has the antigen-binding domain of
the antibody is then used for therapeutic application. The drawback in using the Fab region
of the antibody is its reduced half-life due to renal clearance [81, 82]. In addressing these
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challenges, bispecific antibodies (BsAb) were developed in 1961 [83]. Just as their name implies,
this class of antibodies binds two different antigens or two different epitopes on the same
region.
Figure 5. (A) Different forms of bispecific antibody. Trifunctional antibodies consist of two heavy and two light chains
from two different antibodies. This results in an antibody with binding sites for two different antigens as well as an Fc
region made up of two heavy chains forming a third binding site. A diabody consists of scFvs with very short linker
peptides that force the closely positioned variable regions to fold together, forcing the scFvs to dimerize. Chemically
coupled Fabs consist of the antigen-binding regions of two different monoclonal antibodies linked by a chemical
means. Bispecific T-cell antigens are fusion proteins of two scFvs from four separate genes. (B) Development of bispe‐
cific compounds. Bispecific compounds enable simultaneous inhibition of two cell surface receptors, simultaneous
blocking of two ligands, cross-linking of two receptors, and/or the recruitment of T cells to the proximity of tumor cells
(redirected immune cell killing).
BsAb represent a class of antibodies that are yet to be fully explored in the treatment of cancer
and other diseases. BsAb have a greater potential therapeutic efficiency than mono-targeted
therapy, since they allow simultaneous engagements of two targets and limit potential escape
pathways [84–86]. Numerous studies have shown that there is evidence of cross talk between
receptor tyrosine kinases such as MET, VEGFR, and IGFR-IR which are known to promote
cancer progression and drug resistance. And patients with colon cancer are known not to
respond to anti-EGFR drugs with resistance emerging after initial usage [87, 88]. Engelman et
al. showed that MET amplification leads to gefitinib resistance by activating the ERBB3
pathway, showing the complexity of tumor signaling pathways and a need to treat patients
with drugs that target multiple targets [89].
In the use of BsAb, T cells are targeted because of their high cytotoxic retention, abundance in
bloodstream, surveillance function, and proven ability to control malignant diseases [90, 91].
During cancer progression, cancer cells escape immune recognition by interfering with antigen
presentation or T-cell activation or differentiation. In using the bispecific antibody, most
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targeted antigens for tumor therapy are differentiation antigens such as CD19, CD33, CEA,
EpCAM Epithelial cell adhesion molecule, PMSA Prostate-specific membrane antigen , and
EGF receptors. In most cases these antigens are overexpressed in cancer cells compared to the
normal cells.
Blinatumomab is an example of a bispecific antibody that has shown great promise clinically
in cancer patients. Blinatumomab is a 55 kDa-fusion protein comprised of two single-chain
antibodies to CD19 and CD3, recombinantly joined by a flexible, non-glycosylated five-amino
acid non-immunogenic linker that affords a very short distance between arms [92, 93].
Blinatumomab has high affinity for CD19 which is important in sustaining the malignant B-
cell phenotype via mechanisms of proliferation, cell survival, and self-renewal [94, 95]. It draws
malignant B cells in close proximity to CD3-positive T cells without regard to TCR specificity
or reliance on MHC class I molecules on the surface of APCs for activation. The nonspecific
binding of the polyclonal T-cell population prevents resistances to T-cell-based therapies as a
result of downregulation of MHC molecules. CD19 and CD3 binding results in T-cell activa‐
tion, marked by upregulation of T-cell activation markers CD25, CD69, CD2, IFN-γ, TNFα,
and IL-2, IL-6, and IL-10 [96]. Cell lysis is mediated by secretion of perforin and various
granzymes stored in the secretory vesicles of cytotoxic T cells [97]. In vitro data suggest that
efficacy of blinatumomab is not compromised or dependent upon T cells, which may be limited
in number in heavily pretreated patients [98]. Also blinatumomab-activated T cells appear to
effectively induce serial target cell killing [92, 93].
8. Adoptive immunotherapy
In the wake of cancer treatment challenges or therapies, adoptive immunotherapy is one of
the novel strategies being researched for cancer treatment. This concept was presented five
decades ago [99–101] and is based on the transfer of ex vivo expanded antitumor CD8 T cells
into affected patients (Figure 6). Delorme and Alexander [101] showed that the transfer of
immune lymphocytes could inhibit the growth rate of carcinogen-induced sarcoma.
The immune system is responsible for the prevention of tumors or elimination of pathogens
that can cause inflammation or an inflammatory environment for tumorigenesis or destroy
tumor cells expressing TSAs or molecules induced by stress [102, 103]. Therefore, tumor
development and progression are largely dependent on the patient’s immune system to
effectively inhibit cancer growth using its network of immune cell types. Each and every cell
type has a specific function in inhibiting tumor growth (Figure 7). Consequently, the success
of adoptive immunotheraphy depends on approaches which will target different immune
subsets.
Adoptive immunotherapies have explored the use of infiltrating T cells (CD8+ effector T cells
and CD8+ effector memory cells), NK cells, and IL-2 for cancer-targeted therapies. The T cells
are able to destroy tumor cells using cytotoxic granules containing perforin and granzymes
and by using cell surface receptor such as TNF-related apoptosis-inducing ligand [104, 105].
Studies using mice have shown that adoptive transfer of T cells successfully induces antitumor
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response. Also, only a small number is required to mediate effective regression of tumor and
survival [106–108]. Genetic modification of T cells has been successfully used to broaden their
effective application by pairing with antigen receptors that recognize a range of different
TAAs. Genetic engineering has also been employed to alter T cells so that they are able to avoid
or be resistant to immune invasion strategies used by tumors such as the production of
cytokines. Another modification of T cells involves attaching stimulatory signals for their
activation [109, 110].
NK cells target and kill diseased cells using various mechanisms such as perforins and
granzyme. The use of NK cells was first explored by Rosenberg et al. [111]. Lymphokine-
activated killer cells were co-administered with IL-2 and resulted in a positive response in
people with metastatic cancer [111]. Another combination of chemotherapy with transfer of
allogeneic NK cells resulted in disease remission [112]. It is anticipated that a hybrid of T and
NK cell will have great potential in the treatment of cancer using adoptive immunotherapy.
However we are still a long way from the development of such a model treatment that can be
developed for clinical trials and introduced into clinical practice.
Figure 6. Different techniques used in adoptive immunotherapy. Adoptive immunotherapy with functional T cells can
be performed in numerous ways. Exhaustion of antigen-specific T cells which can be a major problem in the practical
application of this therapy can be solved through reprogramming clonally expanded antigen-specific CD8+ T cells and
then redirecting their redifferentiation into CD8+ T cells possessing antigen-specific killing activity. T cells can be isolat‐
ed from the patient. Isolated peptide antigens could be used to stimulate T cells that are already present in the patient's
tumor or be used to prime tumor-specific T cells. If the T-cell populations generated are specific for the patient's tumor,
they could be expanded and adoptively transferred if they are of human origin. T cells can be genetically engineered to
recognize TAAs. TCRs from T cells that show a good antitumor response can be cloned and inserted into retroviruses,
which are used to infect autologous T cells from the patient. Chimeric antigen receptors (CARs) can be generated
through genetic engineering and then cloned into a retroviral vector and used to infect T cells from the patient. TCRs
can also be isolated from humanized mice that express human MHC molecules and can be immunized with the tumor
antigen of interest. Mouse T cells can then be isolated, and their TCR genes are cloned into recombinant vectors that
can be used to genetically engineer autologous T cells from the patient.
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9. Conclusion
The final goal of immunotherapeutic strategies to treat colon cancer would be the development
of tumor-specific therapies that can be used in conjunction with standard chemotherapies with
little side effects. The use of various combinations of different antibodies and OVs with
synergistic antitumor activity and reduced toxicity will aim to achieve durable tumor eradi‐
cation. One of the main obstacles is the identification of tumor-specific and essential tumor
antigens. These antigens may differ with different tumors. In terms of checkpoint inhibition,
it is important to establish the correct level of inhibition each patient requires to minimize
toxicity. Another important goal is the identification and development of biomarkers to serve
as prognostic markers for the monitoring of the individual patients response to immunother‐
apy, allowing for the identification of those patients who are most likely to benefit from these
treatments. These goals require extensive further studies to refine immunotherapeutic
strategies and combinatorial approaches.
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Figure 7. White blood cell types and mechanisms of response against tumors. The diagram illustrates all of the differ‐
ent immune-related cell types including T cells, NK, macrophages, eosinophils, and neutrophils that are able to re‐
spond against cancer cells. The method of response against the tumor cells is also indicated. In some cases these cell
types can cooperate to produce additional responses.
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